Regeneron Pharmaceuticals has expanded its ophthalmology portfolio, acquiring exclusive rights to two antibodies invented at Regeneron and previously part of its collaboration with Sanofi. The antibodies target the PDGF (platelet derived growth factor) family of receptors and ligands in ophthalmology and all other indications. Antibodies to PDGF and ANG2 are currently in preclinical development for use in ophthalmology.   Regeneron will pay Sanofi $10 million upfront, as much as $40 million in d...